1. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Issue 10023 (12th March 2016) Authors: Ledermann, Jonathan A; Embleton, Andrew C; Raja, Fharat; Perren, Timothy J; Jayson, Gordon C; Rustin, Gordon J S; Kaye, Stan B; Hirte, Hal; Eisenhauer, Elizabeth; Vaughan, Michelle; Friedlander, Michael; González-Martín, Antonio; Stark, Daniel; Clark, Elizabeth; Farrelly, Laura; Swart, Ann Marie;... Journal: Lancet Issue: Volume 387:Issue 10023(2016) Page Start: 1066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Docetaxel in the management of ovarian cancer. Issue 2 (April 2005) Authors: Blagden, Sarah P; Kaye, Stan B Journal: Expert review of anticancer therapy Issue: Volume 5:Issue 2(2005) Page Start: 203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. Issue 5 (11th March 2021) Authors: Hoppe, Michal M; Jaynes, Patrick; Wardyn, Joanna D; Upadhyayula, Sai Srinivas; Tan, Tuan Zea; Lie, Stefanus; Lim, Diana G Z; Pang, Brendan N K; Lim, Sherlly; P S Yeong, Joe; Karnezis, Anthony; Chiu, Derek S; Leung, Samuel; Huntsman, David G; Sedukhina, Anna S; Sato, Ko; Topp, Monique D; Scott, Cl... Journal: EMBO molecular medicine Issue: Volume 13:Issue 5(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗